Engineered Regulatory T Cell Adoptive Therapy As A Novel Tool For The Treatment Of Atherosclerosis

Background and Aims: Loss of anti-inflammatory activity of Tregs has been associated to immunoinflammatory diseases, including atherosclerosis. Therefore, the use of Treg-Adoptive Cell Therapy(ACT) is emerging as a therapeutic strategy to specifically modulate impaired immune responses. Although ACT has produced encouraging results in animal models, a main limitation remains the possibility to target a selected tissue. Our aim was to develop a plaque-homing selective Treg-ACT in models of atherosclerosis.